Dual PI3K/mTOR Inhibitors: Does p53 Modulate Response?  
Oleksandr Ekshyyan, Arunkumar Anandharaj, and Cherie-Ann O. Nathan  
See article, p. 3808

Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals  
Michael B. Shea, Samantha A. Roberts, Jessica C. Walrath, Jeff D. Allen, and Ellen V. Sigal

Molecular Pathways: Environmental Estrogens Activate Nongenomic Signaling to Developmentally Reprogram the Epigenome  
Rebecca Lee Yean Wong and Cheryl Lyn Walker

Molecular Pathways: PI3K Pathway Targets in Triple-Negative Breast Cancers  
Vallerie Gordon and Shantanu Banerji

Optical Image-Guided Cancer Surgery: Challenges and Limitations  

T₉₂ Cytokines from Malignant Cells Suppress T₉₁ Responses and Enforce a Global T₉₂ Bias in Leukemic Cutaneous T-cell Lymphoma  
Emmanueella Guenova, Rei Watanabe, Jessica E. Teague, Jennifer A. Desimone, Ying Jiang, Mitra Dowlatshahi, Christoph Schlapbach, Knut Schuinkel, Alain H. Bok, Marianne Tawa, David C. Fisher, Thomas S. Kupper, and Rachael A. Clark

S100B Promotes Glioma Growth through Chemotraction of Myeloid-Derived Macrophages  
Huaqing Wang, Leying Zhang, Ian Y. Zhang, Xuebo Chen, Anna Da Fonseca, Shihua Wu, Hui Ren, Sam Badie, Sam Sadeghi, Mao Ouyang, Charles D. Warden, and Behnam Badie

Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers  

Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and Paraganglioma  

Functional Profiling of Receptor Tyrosine Kinases and Downstream Signaling in Human Chondrosarcomas Identifies Pathways for Rational Targeted Therapy  
Yi-Xiang Zhang, Jolieke G. van Oosterwijk, Ewa Sicinska, Samuel Moss, Stephen P. Remillard, Tom van Wezel, Claudia Bühnemann, Andrew B. Hassan, George D. Demetri, Judith V.M.G. Boven, and Andrew J. Wagner
PI3K/mTOR Inhibitor PF-04691502 Antitumor Activity Is Enhanced with Induction of Wild-Type TP53 in Human Xenograft and Murine Knockout Models of Head and Neck Cancer


See commentary, p. 3719

Inhibition of GSK3B Bypass Drug Resistance of p53-Null Colon Carcinomas by Enabling Necroptosis in Response to Chemotherapy

Emanuela Grassilli, Robert Narloch, Elena Federzoni, Leonarda Ianzano, Fabio Pisano, Roberto Giovannoni, Gabriele Romano, Laura Masiero, Biagio Eugenio Leone, Serena Bonin, Marisa Donada, Giorgio Stanta, Kristian Helin, and Marialuisa Lavitrano

Leukemia Cell-Rhabdovirus Vaccine: Personalized Immunotherapy for Acute Lymphoblastic Leukemia

David P. Conrad, Jovian Tsang, Meaghan Maclean, Jean-Simon Diallo, Fabrice Le Boeuf, Chantal G. Lemay, Theresa J. Falls, Kelley A. Parato, John C. Bell, and Harold L. Atkins

Targeting Natural Killer Cells to Acute Myeloid Leukemia In Vitro with a CD16×33 Bispecific Killer Cell Engager and ADAM17 Inhibition

Andres Wiernik, Bree Foley, Bin Zhang, Michael R. Verneris, Erica Warlick, Michelle K. Gleason, Julie A. Ross, Xianghua Luo, Daniel A. Vallera, and Jeffrey S. Miller

Therapeutic Potential of HSP90 Inhibition for Neurofibromatosis Type 2


Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts

Rebecca Voltan, Paolo Secchiero, Barbara Ruozzi, Flavio Forni, Chiara Agostinis, Lorenzo Caruso, Maria Angela Vandelli, and Giorgio Zauli

Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway

Lana McClements, Anita Yakkundi, Angelos Papapolympoulos, Hannah Harrison, Matthew P. Ablitt, Puthen V. Jithesh, Hayley D. McKeen, Rachel Bennett, Christopher Donley, Adrien Kissenspenninck, Stuart McIntosh, Helen O. McCarthy, Eric O’Neill, Robert B. Clarke, and Tracy Robson

USPS Is a Novel Target for Overcoming Gefitinib Resistance in Lung Cancer

Sanguine Byun, Sung-Young Lee, Jihoon Lee, Chul-Ho Jeong, Lee Farrand, Semi Lim, Kanamata Reddy, Ji Young Kim, Mee-Hyun Lee, Hyong Joo Lee, Ann M. Bode, Ki Won Lee, and Zigang Dong

Ketogenic Diets Enhance Oxidative Stress and Radio-Chemo-Therapy Responses in Lung Cancer Xenografts


IMAGING, DIAGNOSIS, PROGNOSIS

Temporal and Spatial Evolution of Therapy-Induced Tumor Apoptosis Detected by Caspase-3–Selective Molecular Imaging

Quang-Dé Nguyen, Ioannis Lavdas, James Guibbons, Graham Smith, Robin Fortt, Laurence S. Carroll, Martin A. Graham, and Eric O. Aboagye

Spinophilin Loss Correlates with Poor Patient Prognosis in Advanced Stages of Colon Carcinoma


Developing a Common Language for Tumor Response to Immunotherapy: Immune-Related Response Criteria Using Unidimensional Measurements

Mizuki Nishino, Anita Giobbie-Hurder, Maria Gargano, Margaret Suda, Nikhil H. Ramaiya, and F. Stephen Hodi
Evaluation of Midkine as a Diagnostic Serum Biomarker in Hepatocellular Carcinoma

Wen-Wei Zhu, Jia-Jian Guo, Lei Guo, Hu-Liang Jia, Ming Zhu, Ju-Bo Zhang, Christopher A. Loffredo, Marshonna Forgues, Hua Huang, Xu-Jian Xing, Xiu Qu, Qiong-Zhu Dong, Hai-Jun Zhou, Zheng-Gang Ren, Nai-Qing Zhao, Xin Wei Wang, Zhao-You Tang, Lun-Xiu Qin, and Qing-Hai Ye

The Prognostic Value of MicroRNAs Varies with Patient Race/Ethnicity and Stage of Colorectal Cancer

Liselle C. Bovell, Chandrakumar Shanmugam, Balananda-Dhurjati K. Putcha, Venkat R. Rupam, Bin Zhang, Sejong Bae, Karan P. Singh, William E. Grizzle, and Upender Manne

Antibiotic Treatment Decreases Microbial Burden Associated with Pseudomyxoma Peritonei and Affects β-Catenin Distribution

Cristina Semino-Mora, Traci L. Testerman, Hui Lui, Jeanette M. Whitmire, Kimberley Studeman, Yali Jia, Thomas J. McAvoy, Jennifer Francis, Carol Nieroda, Armando Sardi, D. Scott Merrell, and Andre Dubois

Exposure–Response Relationships of the Efficacy and Safety of Ipilimumab in Patients with Advanced Melanoma

Yan Feng, Amit Roy, Eric Masson, Tai-Tsang Chen, Rachel Humphrey, and Jeffrey S. Weber

Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens

Kimmie Ng, Josep Tabernero, Jimmy Hwang, Emilio Bajetta, Sunil Sharma, Salvatore A. D'Amico, David R. Arrowsmith, David M. Ryan, Michaela Sedova, Jin Jin, Kamel Malek, and Charles S. Fuchs

Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors


Biomarker Modulation following Short-Term Vorinostat in Women with Newly Diagnosed Primary Breast Cancer

Vered Stearns, Lisa K. Jacobs, Marylo Fackler, Theodore N. Tsangaris, Michelle A. Rudek, Michaela Higgins, Julie Lange, Zandra Cheng, Shannon A. Slater, Stacie C. Jeter, Penny Powers, Susanne Breist, Calvin Chao, Carl Yoshizawa, Elizabeth Sugar, Igor Espinoza-Delgado, Saraswati Sukumar, Edward Gabrielson, and Nancy E. Davidson

AC icon indicates Author Choice

CME icon indicates that this article is available for continuing medical education credit at http://cme.aacrjournals.org

For more information please visit www.aacrjournals.org


ABOUT THE COVER

β-catenin is a transmembrane protein that associates with junctional proteins and assists with the maintenance of cell attachment. As revealed through immunofluorescent staining, β-catenin (shown in green) localizes to the cell membranes and within the lateral junctional complex in normal appendix tissue. In contrast, tissue samples from patients with pseudomyxoma peritonei display primarily cytoplasmic staining of β-catenin and virtually no staining at the intercellular boundaries. However, antibiotic treatment of patients with pseudomyxoma peritonei results in a significant increase in β-catenin within the cell membranes, appearing to aid in the renormalization of β-catenin distribution. For details, see the article by Semino-Mora and colleagues on page 3966 of this issue.